VOTRIENT® (pazopanib) – Important Change to Frequency of Serum Liver Test Monitoring for Hepatotoxicity

GlaxoSmithKline would like to inform healthcare professionals of an important safety update regarding a change in frequency of serum liver test monitoring for hepatotoxicity during use of VOTRIENT®. VOTRIENT® is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma and for patients who have received prior cytokine therapy for advanced disease. Healthcare professionals are advised to monitor serum liver tests before initiating VOTRIENT® and at weeks 3, 5, 7, and 9. Thereafter, patients should be monitored at Month 3 and Month 4, and as clinically indicated. Periodic monitoring should continue after Month 4.

 
 
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.